The results reported herein areexpected to benefit medicinal chemists working on the developmentof selective MTHFD2 inhibitors for cancer treatment, although experimentalvalidation by biochemical and/or pharmacokinetic assays is requiredto substantiate the outcomes of the study. This evidence concerns the gene MTHFD2 and cancer.